ArticleJournal of orthopaedic surgery and research2025
Analysis of miR-151a-3p as a biomarker of osteoarthritis and its clinical value.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epigenetic modulation of the JAK2-STAT3 signaling pathway in osteoporosis: non-coding RNA networks as therapeutic targets.Journal of translational medicine · 2026Review
- Elevated miR-409-5p may promote the progression of osteoarthritis by targeting DLST as a potential biomarker function of miR-409-5p in osteoarthritis.Journal of orthopaedic surgery and research · 2026Article
- Diagnostic value and prognostic effect of has-miR-151a-3p in tuberculosis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026Article
- Mitochondrial quality control modulating chondrocyte behavior and fate in knee osteoarthritis: mechanistic insights and therapeutic prospects.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic strategies that focus on chondrocyte protection and matrix repair may represent a key direction for delaying the progression of osteoarthritis (OA).
aimTo evaluate miR-151a-3p as a biomarker for the diagnosis of OA and its potential mechanism of action. MATERIALS AND
methodsRT-qPCR was used to determine miR-151a-3p and SOX9 expression levels in OA patients and lipopolysaccharide-induced OA (LPS-OA) cell model. The receiver operating characteristic (ROC) curve was used to analyze the clinical value of miR-151a-3p in the diagnosis of OA. A cell function experiment was conducted to investigate the impact of miR-151a-3p on cell viability and apoptosis levels in the LPS-induced OA cell model. Genecards and starBase were used to screen the target genes of miR-151a-3p. The dual luciferase reporter assay was used to verify the interaction between miR-151a-3p and SOX9.
resultsThe expression of miR-151a-3p was up-regulated in synovial fluid of OA patients and LPS-OA cell model. The ROC curve analysis and logistic regression analysis demonstrated that miR-151a-3p could be a potential biomarker for the diagnosis of OA and exhibited significant diagnostic value. Genecards and starBase databases screened 6 potential targets of miR-151a-3p. Dual luciferase reporter assay demonstrated that miR-151a-3p targeted SOX9. Cell function experiments demonstrated that suppressed miR-151a-3p can upregulate SOX9 expression, thereby enhancing LPS-OA cell activity, reducing apoptosis, and increasing extracellular matrix (ECM) production.
conclusionMiR-151a-3p could be a biomarker for the diagnosis of OA and has high diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.